BusinessBeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 9, 2017, 2:00 PM UTC
BusinessArQule Reports Fourth Quarter and Full Year 2015 Financial ResultsBy Nasdaq OMXFeb 29, 2016, 12:00 PM UTC
